LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 91

Search options

  1. Article ; Online: Polymyalgia Rheumatica or Late Onset Lupus? A Case Report.

    Altier, Jake / Oates, Jim / Ward, Celine

    Journal of investigative medicine high impact case reports

    2022  Volume 10, Page(s) 23247096221089493

    Abstract: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a peak age of presentation between the 15 and 40 years with a wide variety of disease manifestations. Although there is no formal definition, late onset SLE is generally defined ... ...

    Abstract Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a peak age of presentation between the 15 and 40 years with a wide variety of disease manifestations. Although there is no formal definition, late onset SLE is generally defined in the literature as onset after the age of 50. It is estimated that 2% to 20% of patients with SLE overall fall into this category. It is important for the clinician to recognize this less-common entity because arthralgia, myalgia, fatigue, and sicca symptoms in the elderly can so easily be attributed as symptoms of normal aging or other common degenerative processes rather than a systemic disease similar to SLE or Sjogren's syndrome. The following report outlines a case of late onset SLE which initially was suspected to be polymyalgia rheumatica (PMR).
    MeSH term(s) Adolescent ; Adult ; Aged ; Giant Cell Arteritis ; Humans ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/diagnosis ; Polymyalgia Rheumatica/complications ; Polymyalgia Rheumatica/diagnosis ; Sjogren's Syndrome/complications ; Sjogren's Syndrome/diagnosis ; Young Adult
    Language English
    Publishing date 2022-04-06
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2710326-2
    ISSN 2324-7096 ; 2324-7096
    ISSN (online) 2324-7096
    ISSN 2324-7096
    DOI 10.1177/23247096221089493
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Endothelial cells: potential novel regulators of renal inflammation.

    Oates, Jim C / Russell, Dayvia L / Van Beusecum, Justin P

    American journal of physiology. Renal physiology

    2022  Volume 322, Issue 3, Page(s) F309–F321

    Abstract: Substantial evidence has supported the role of endothelial cell (EC) activation and dysfunction in the development of hypertension, chronic kidney disease (CKD), and lupus nephritis (LN). In both humans and experimental models of hypertension, CKD, and ... ...

    Abstract Substantial evidence has supported the role of endothelial cell (EC) activation and dysfunction in the development of hypertension, chronic kidney disease (CKD), and lupus nephritis (LN). In both humans and experimental models of hypertension, CKD, and LN, ECs become activated and release potent mediators of inflammation including cytokines, chemokines, and reactive oxygen species that cause EC dysfunction, tissue damage, and fibrosis. Factors that activate the endothelium include inflammatory cytokines, mechanical stretch, and pathological shear stress. These signals can activate the endothelium to promote upregulation of adhesion molecules, such as intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, which promote leukocyte adhesion and migration to the activated endothelium. More importantly, it is now recognized that some of these signals may in turn promote endothelial antigen presentation through major histocompatibility complex II. In this review, we will consider in-depth mechanisms of endothelial activation and the novel mechanism of endothelial antigen presentation. Moreover, we will discuss these proinflammatory events in renal pathologies and consider possible new therapeutic approaches to limit the untoward effects of endothelial inflammation in hypertension, CKD, and LN.
    MeSH term(s) Cytokines/metabolism ; Endothelial Cells/metabolism ; Endothelium, Vascular/metabolism ; Female ; Humans ; Hypertension/metabolism ; Inflammation/metabolism ; Intercellular Adhesion Molecule-1/metabolism ; Lupus Nephritis/metabolism ; Male ; Renal Insufficiency, Chronic/metabolism ; Vascular Cell Adhesion Molecule-1/metabolism
    Chemical Substances Cytokines ; Vascular Cell Adhesion Molecule-1 ; Intercellular Adhesion Molecule-1 (126547-89-5)
    Language English
    Publishing date 2022-02-07
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
    ZDB-ID 603837-2
    ISSN 1522-1466 ; 0363-6127
    ISSN (online) 1522-1466
    ISSN 0363-6127
    DOI 10.1152/ajprenal.00371.2021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Polymyalgia Rheumatica or Late Onset Lupus? A Case Report

    Jake Altier MD / Jim Oates MD / Celine Ward MD

    Journal of Investigative Medicine High Impact Case Reports, Vol

    2022  Volume 10

    Abstract: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a peak age of presentation between the 15 and 40 years with a wide variety of disease manifestations. Although there is no formal definition, late onset SLE is generally defined ... ...

    Abstract Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a peak age of presentation between the 15 and 40 years with a wide variety of disease manifestations. Although there is no formal definition, late onset SLE is generally defined in the literature as onset after the age of 50. It is estimated that 2% to 20% of patients with SLE overall fall into this category. It is important for the clinician to recognize this less-common entity because arthralgia, myalgia, fatigue, and sicca symptoms in the elderly can so easily be attributed as symptoms of normal aging or other common degenerative processes rather than a systemic disease similar to SLE or Sjogren’s syndrome. The following report outlines a case of late onset SLE which initially was suspected to be polymyalgia rheumatica (PMR).
    Keywords Medicine (General) ; R5-920 ; Pathology ; RB1-214
    Language English
    Publishing date 2022-04-01T00:00:00Z
    Publisher SAGE Publishing
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Endothelial dysfunction in injury and inflammation.

    Oates, Jim C

    The American journal of the medical sciences

    2014  Volume 349, Issue 1, Page(s) 2

    MeSH term(s) C-Reactive Protein/metabolism ; Endothelial Cells/metabolism ; Endothelium, Vascular/metabolism ; Endothelium, Vascular/physiology ; Inflammation/metabolism ; Inflammation/physiopathology ; Liver Cirrhosis/metabolism ; Nitric Oxide/metabolism ; Nitric Oxide Synthase Type III/metabolism ; Vascular Diseases/metabolism ; Vascular Diseases/physiopathology
    Chemical Substances Nitric Oxide (31C4KY9ESH) ; C-Reactive Protein (9007-41-4) ; Nitric Oxide Synthase Type III (EC 1.14.13.39)
    Language English
    Publishing date 2014-12-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82078-7
    ISSN 1538-2990 ; 0002-9629
    ISSN (online) 1538-2990
    ISSN 0002-9629
    DOI 10.1097/MAJ.0000000000000401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Association Between the Anti-Aging Gene Klotho and Selected Rheumatologic Autoimmune Diseases.

    Russell, Dayvia L / Oates, Jim C / Markiewicz, Margaret

    The American journal of the medical sciences

    2020  Volume 361, Issue 2, Page(s) 169–175

    Abstract: Klotho long recognized for its role in anti-aging, is potentially implicated in the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. Aging of the immune system coincides with the inability of the body to ... ...

    Abstract Klotho long recognized for its role in anti-aging, is potentially implicated in the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. Aging of the immune system coincides with the inability of the body to recognize self-antigens, which often leads to autoimmune responses. The role of Klotho in these autoimmune diseases should be of high interest; however, few articles have been published exploring the role of Klotho in the pathogenesis, organ involvement, or clinical manifestation of rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. Herein, we discuss information gathered from peer-reviewed publications to describe the emerging role of Kl in these select rheumatologic autoimmune diseases.
    MeSH term(s) Aging/genetics ; Animals ; Autoimmune Diseases/genetics ; Glucuronidase/genetics ; Humans ; Klotho Proteins ; Rheumatic Diseases/genetics ; Scleroderma, Systemic/genetics
    Chemical Substances Glucuronidase (EC 3.2.1.31) ; Klotho Proteins (EC 3.2.1.31)
    Language English
    Publishing date 2020-10-25
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
    ZDB-ID 82078-7
    ISSN 1538-2990 ; 0002-9629
    ISSN (online) 1538-2990
    ISSN 0002-9629
    DOI 10.1016/j.amjms.2020.10.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The magic of the Southern Society for Clinical Investigation: can we make the vanishing physician-scientist reappear?

    Oates, Jim C

    The American journal of the medical sciences

    2013  Volume 345, Issue 4, Page(s) 259

    MeSH term(s) Biomedical Research/trends ; Clinical Trials as Topic ; Physician's Role ; Societies, Medical
    Language English
    Publishing date 2013-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82078-7
    ISSN 1538-2990 ; 0002-9629
    ISSN (online) 1538-2990
    ISSN 0002-9629
    DOI 10.1097/MAJ.0b013e31828a21ce
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: DEFINING THE MEDICAL RECORD: RELATIONSHIPS OF THE LEGAL MEDICAL RECORD, THE DESIGNATED RECORD SET, AND THE ELECTRONIC HEALTH RECORD.

    Floyd, Phyllis T / Oates, Jim C / Acker, Julie W / Warren, Robert W

    Perspectives in health information management

    2021  Volume 18, Issue 4, Page(s) 1h

    Abstract: Not so long ago, defining the "medical record" was simple. It was the paper chart-volume upon volume that captured the serial, dutifully recorded events of a person's health care at a hospital or physician's office. Entries were typically handwritten, ... ...

    Abstract Not so long ago, defining the "medical record" was simple. It was the paper chart-volume upon volume that captured the serial, dutifully recorded events of a person's health care at a hospital or physician's office. Entries were typically handwritten, dated and timed, and signed in ink with title (i.e., authenticated). Errors were easily identified by an authenticated strike-through. Similarly, the paper chart was synonymous with the legal medical record (LMR). In other words, a patient's paper chart was that patient's LMR by definition, even if critical data was omitted or irrelevant data was included. Fast-forward to 2021 and the use of technology for capturing the record of a patient's care. Technology has brought new challenges as well as successes. For example, pervasive and persistent mythologies include that 1) a patient's electronic health record (EHR) is the LMR, and 2) patient-specific EHR printouts to paper or disc-or displays on monitors-are necessarily equivalents to the paper chart of the 1980s. Neither are true. We now must define at the outset what is included in the LMR/designated record set to ensure the accuracy of what is retained and released.
    MeSH term(s) Electronic Health Records ; Humans
    Language English
    Publishing date 2021-10-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2422433-9
    ISSN 1559-4122 ; 1559-4122
    ISSN (online) 1559-4122
    ISSN 1559-4122
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells.

    Russell, Dayvia A / Markiewicz, Margaret / Oates, Jim C

    Lupus science & medicine

    2020  Volume 7, Issue 1

    Abstract: Objectives: SLE is associated with endothelial cell dysfunction (ECD). Understanding how ECD leads to neutrophil infiltration into glomeruli is essential to finding therapeutic targets for SLE. The aim of this study is to determine the effect of SLE ... ...

    Abstract Objectives: SLE is associated with endothelial cell dysfunction (ECD). Understanding how ECD leads to neutrophil infiltration into glomeruli is essential to finding therapeutic targets for SLE. The aim of this study is to determine the effect of SLE serum from patients with active disease to induce neutrophil adhesion to and chemotaxis towards glomerular endothelial cells and factors induced by serum that associate with neutrophil chemotaxis.
    Methods: Patients with SLE had serum collected during paired longitudinal visits with lower and higher activity. 13 patients with SLE (5 SLE, 5 SLE with hypertension (HTN) and 3 SLE lupus nephritis (LN) and HTN), and 10 healthy controls (5 with and 5 without HTN) were examined. The adhesion of neutrophils to serum-treated human renal glomerular endothelial cells (HRGECs) or chemotaxis of neutrophils towards conditioned media from serum-treated HRGECs was determined, and levels of cytokines in this conditioned medium were quantified. Pathway analysis of cytokines induced by SLE and LN serum that associated with neutrophil migration was performed.
    Results: HRGECs treated with SLE serum induced significantly greater neutrophil chemotaxis and adhesion compared with control serum. When examining specific cohorts, SLE HTN and LN HTN promoted greater neutrophil chemotaxis than control serum, while SLE HTN and LN HTN promoted greater chemotaxis than SLE serum. Serum from active disease visits promoted neutrophil chemotaxis and adhesion over paired inactive visits. Levels of platelet-derived growth factor-BB, interleukin (IL)-15 and IL-8 secreted by SLE serum-treated HRGECs positively correlated with neutrophil chemotaxis. Pathway analysis suggested that LN serum induced pathways important in endoplasmic reticulum and oxidative stress.
    Conclusions: SLE serum induces expression of mediators by HRGECs that promote neutrophil chemotaxis and adhesion, which increases during disease activity, and associates with factors common to pathways of endoplasmic reticulum and oxidative stress. These findings highlight the potential importance of serum factor-induced ECD in SLE and LN.
    MeSH term(s) Adult ; Endothelial Cells ; Female ; Humans ; Kidney ; Kidney Glomerulus ; Lupus Nephritis ; Male ; Middle Aged ; Neutrophils
    Language English
    Publishing date 2020-10-06
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2779620-6
    ISSN 2053-8790
    ISSN 2053-8790
    DOI 10.1136/lupus-2020-000418
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Variable selection methods for identifying predictor interactions in data with repeatedly measured binary outcomes.

    Wolf, Bethany J / Jiang, Yunyun / Wilson, Sylvia H / Oates, Jim C

    Journal of clinical and translational science

    2020  Volume 5, Issue 1, Page(s) e59

    Abstract: Introduction: Identifying predictors of patient outcomes evaluated over time may require modeling interactions among variables while addressing within-subject correlation. Generalized linear mixed models (GLMMs) and generalized estimating equations ( ... ...

    Abstract Introduction: Identifying predictors of patient outcomes evaluated over time may require modeling interactions among variables while addressing within-subject correlation. Generalized linear mixed models (GLMMs) and generalized estimating equations (GEEs) address within-subject correlation, but identifying interactions can be difficult if not hypothesized
    Methods: We conducted simulations comparing stepwise selection, penalized GLMM, boosted GLMM, and boosted GEE for variable selection considering main effects and two-way interactions in data with repeatedly measured binary outcomes and evaluate a two-stage approach to reduce bias and error in parameter estimates. We compared these approaches in real data applications: hypothermia during surgery and treatment response in lupus nephritis.
    Results: Penalized and boosted approaches recovered correct predictors and interactions more frequently than stepwise selection. Penalized GLMM recovered correct predictors more often than boosting, but included many spurious predictors. Boosted GLMM yielded parsimonious models and identified correct predictors well at large sample and effect sizes, but required excessive computation time. Boosted GEE was computationally efficient and selected relatively parsimonious models, offering a compromise between computation and parsimony. The two-stage approach reduced the bias and error in regression parameters in all approaches.
    Conclusion: Penalized and boosted approaches are effective for variable selection in data with clustered binary outcomes. The two-stage approach reduces bias and error and should be applied regardless of method. We provide guidance for choosing the most appropriate method in real applications.
    Language English
    Publishing date 2020-11-16
    Publishing country England
    Document type Journal Article
    ISSN 2059-8661
    ISSN (online) 2059-8661
    DOI 10.1017/cts.2020.556
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity.

    Yelnik, Cécile M / Xie, Xianhong / Guerra, Marta M / Costedoat-Chalumeau, Nathalie / Khosroshahi, Arezou / Kamen, Diane L / Schwartz, Noa / Katz, Patricia / Minett, Margaret / Amoss, R Toby / Fu, April / Guettrot-Imbert, Gaëlle / Lazaro, Estibaliz / Le Guern, Véronique / Oates, Jim / Dall'Era, Maria / Yazdany, Jinoos / Molto, Anna / Kim, Mimi Y /
    Salmon, Jane E

    Annals of the rheumatic diseases

    2024  Volume 83, Issue 3, Page(s) 404–406

    MeSH term(s) Humans ; Antibodies, Antiphospholipid ; Prevalence ; Ethnicity ; Lupus Erythematosus, Systemic ; Antiphospholipid Syndrome
    Chemical Substances Antibodies, Antiphospholipid
    Language English
    Publishing date 2024-02-15
    Publishing country England
    Document type Letter
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/ard-2023-224952
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top